Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

8.0%

2 terminated/withdrawn out of 25 trials

Success Rate

89.5%

+3.0% vs industry average

Late-Stage Pipeline

40%

10 trials in Phase 3/4

Results Transparency

59%

10 of 17 completed trials have results

Key Signals

3 recruiting10 with results

Enrollment Performance

Analytics

Phase 3

8(38.1%)

N/A

7(33.3%)

Phase 1

2(9.5%)

Phase 2

2(9.5%)

Phase 4

2(9.5%)

21Total

Phase 3(8)

N/A(7)

Phase 1(2)

Phase 2(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials

NCT07457918Phase 3Recruiting

Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)

Role: collaborator

NCT05267613Phase 3Active Not Recruiting

Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.

Role: collaborator

NCT06639828Phase 4Recruiting

Phase 4 Paediatric Study to Evaluate Sonazoid Safety and Efficacy for Contrast-Enhanced Ultrasound Liver Imaging

Role: collaborator

NCT07246590Phase 3Recruiting

Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)

Role: collaborator

NCT04763512Not ApplicableCompleted

Clinical Study of Partially Hydrolysed Protein Infant Formula on Trans-epidermal Water Loss (TEWL)

Role: collaborator

NCT00981058Phase 3Completed

First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Role: collaborator

NCT05054309Not ApplicableCompleted

A Trial to Evaluate the Effects of Bifidobacterium Longum NCC3001 on Intestinal and Psychological Symptoms in Subjects With Irritable Bowel Syndrome

Role: collaborator

NCT01110460Completed

Prospective Study on Asthma Control

Role: collaborator

NCT03714815Phase 2Terminated

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease

Role: collaborator

NCT04078152Phase 4Completed

Durvalumab Long-Term Safety and Efficacy Study

Role: collaborator

NCT04201132Not ApplicableActive Not Recruiting

Protection Against Emboli During Carotid Artery Stenting Using the Neuroguard IEP System

Role: collaborator

NCT04566653Completed

Patient Palatability and Preference of 3 Potassium Binders in Patients With Chronic Kidney Disease and Hyperkalaemia

Role: collaborator

NCT03775421Phase 3Terminated

An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.

Role: collaborator

NCT00982111Phase 3Completed

First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin

Role: collaborator

NCT02586155Phase 3Completed

Effect of RVX000222 on Time to Major Adverse Cardiovascular Events in High-Risk T2DM Subjects With CAD

Role: collaborator

NCT02697916Not ApplicableCompleted

Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term

Role: collaborator

NCT04699643Phase 1Unknown

FGFR4 Inhibitor EVER4010001 in Combination With PD-1 Inhibitor Pembrolizumab in Patients With Advanced Solid Tumors

Role: collaborator

NCT01007032Phase 1Completed

A Study of IMC-A12 in Advanced Solid Tumors

Role: collaborator

NCT01148329Completed

PROMUS™ Element™ Everolimus-Eluting Coronary Stent System European Post-Approval Surveillance Study

Role: collaborator

NCT02589236Phase 2Completed

Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation

Role: collaborator